Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474451 | 0.94 | EGLN1 (0.39) | EGLN1EGLN2EGLN3HDAC3HDAC4 | |
| SCHEMBL2518895 | 0.88 | EGLN1 (0.37) | EGLN1EGLN2EGLN3KDM4EALDH1A1 | |
| SCHEMBL2470821 | 0.87 | EGLN1 (0.45) | EGLN1EGLN2EGLN3HDAC3HDAC4 | |
| SCHEMBL2473839 | 0.85 | EGLN1 (0.43) | EGLN1EGLN2EGLN3HDAC3HDAC4 | |
| SCHEMBL2761588 | 0.85 | EGLN1 (0.44) | EGLN1EGLN2EGLN3 | |
| SCHEMBL2497884 | 0.81 | EGLN1 (0.42) | EGLN1EGLN2EGLN3HDAC3HDAC4 | |
| SCHEMBL28019091 | 0.81 | HDAC3 (0.38) | EGLN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2469234 | 0.79 | EGLN2 (0.45) | EGLN1EGLN2EGLN3 | |
| SCHEMBL2472709 | 0.77 | STIM1 (0.37) | EGLN1EGLN2HDAC3HDAC4HDAC1 | |
| SCHEMBL2470202 | 0.76 | EGLN1 (0.46) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | claimed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | claimed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | claimed |
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 4/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.